Novel antipsychotics for patients with attention-deficit hyperactivity disorder: a systematic review

Einarson T R, Iskedjian M
Record ID 32002000017
English, French
Authors' objectives:

This report aims to answer the following questions:

- What does the existing evidence say about the efficacy and safety of novel antipsychotics for treating children and adolescents with attention-deficit hyperactivity disorder (ADHD)?

- What are the financial implications, in terms of additional drug acquisition costs, for the Canadian health care system if novel antipsychotics were to be adopted for this indication?

Authors' results and conclusions: Efficacy: A formal meta-analysis could not be performed due to the lack of data. Case studies considering the use of risperidone and olanzapine, either alone or as add-on therapy with methylphenidate, for the treatment of ADHD reported successes, failures and discontinuations due to adverse events. As those studies are not controlled or comparative, it was not possible to draw any conclusions about the efficacy of the treatment. Safety: A total of 549 children and adolescents were reported to have taken either risperidone or olanzapine in 49 Level III studies. There were no accounts of pediatric quetiapine use in the literature. The most common adverse drug reaction (ADR) was sedation, which usually dissipated either on its own or after a dose reduction. Many children experienced weight gain. The literature also reported extrapyramidal effects in 4% of the patients.
Authors' recommendations: As the quality of the existing evidence is quite weak, no conclusions can be drawn concerning the efficacy of novel antipsychotics for treating children and adolescents with ADHD.
Authors' methods: Systematic review
Project Status: Completed
URL for project:
Year Published: 2001
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Canada
MeSH Terms
  • Antipsychotic Agents
  • Attention Deficit Disorder with Hyperactivity
Organisation Name: Canadian Coordinating Office for Health Technology Assessment
Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name:
Contact Email:
Copyright: Canadian Coordinating Office for Health Technology Assessment (CCOHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.